What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
Nizar M. Tannir mainly investigates Internal medicine, Renal cell carcinoma, Surgery, Carcinoma and Oncology.
His work on Gastroenterology expands to the thematically related Internal medicine.
He combines subjects such as Survival rate, Targeted therapy and Kidney disease with his study of Renal cell carcinoma.
The Surgery study combines topics in areas such as Radiofrequency ablation, Everolimus, Nephrectomy and Urology.
His studies deal with areas such as Immunology, Metastasis, Survival analysis and Combination therapy as well as Carcinoma.
His studies in Oncology integrate themes in fields like Temsirolimus and Alpha interferon.
His most cited work include:
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma (1476 citations)
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma (637 citations)
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial (474 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Internal medicine, Renal cell carcinoma, Oncology, Surgery and Cancer research.
His work on Sunitinib, Cancer, Nivolumab and Clear cell renal cell carcinoma as part of general Internal medicine research is frequently linked to In patient, bridging the gap between disciplines.
His Renal cell carcinoma study also includes
- Carcinoma, which have a strong connection to Survival rate,
- Urology that connect with fields like Cytoreductive nephrectomy.
His Oncology study combines topics in areas such as Bevacizumab, Clinical trial, Prostate cancer and Sorafenib.
His research integrates issues of Gastroenterology, Adverse effect, Kidney disease and Primary tumor in his study of Surgery.
His study in Cancer research is interdisciplinary in nature, drawing from both Carcinogenesis and Immune system.
He most often published in these fields:
- Internal medicine (55.13%)
- Renal cell carcinoma (51.47%)
- Oncology (43.41%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (55.13%)
- Renal cell carcinoma (51.47%)
- Oncology (43.41%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Renal cell carcinoma, Oncology, Nivolumab and Cancer research.
His Internal medicine study often links to related topics such as Gastroenterology.
His biological study spans a wide range of topics, including Immunotherapy, Retrospective cohort study and Urology.
As a part of the same scientific study, Nizar M. Tannir usually deals with the Oncology, concentrating on Hazard ratio and frequently concerns with Clinical endpoint.
His Nivolumab research incorporates elements of Receptor, Tolerability, Ipilimumab and CD8.
His work in Cancer research addresses issues such as Renal medullary carcinoma, which are connected to fields such as Kidney and Malignancy.
Between 2017 and 2021, his most popular works were:
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma (1476 citations)
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. (468 citations)
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (204 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His primary scientific interests are in Internal medicine, Renal cell carcinoma, Oncology, Nivolumab and Sunitinib.
In most of his Internal medicine studies, his work intersects topics such as Gastroenterology.
His Renal cell carcinoma research incorporates themes from Progressive disease, Clinical trial, Discontinuation, Urology and Carcinoma.
Oncology is closely attributed to Hazard ratio in his study.
The various areas that Nizar M. Tannir examines in his Nivolumab study include Ipilimumab and CD8.
His work in Sunitinib covers topics such as Targeted therapy which are related to areas like Post hoc and Sarcomatoid Features.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
